Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura
- 6 February 2009
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 82 (s71) , 20-25
Abstract
Initially, immune (idiopathic) thrombocytopenic purpura (ITP) was considered to be a disease of increased platelet destruction. Consequently, treatments for ITP patients were focused on reducing the destruction of platelets. However, recent research on the pathogenesis of ITP points to a role of suboptimal platelet production, and this has led to the development of new treatment options which increase platelet production such as the novel thrombopoiesis‐stimulating agent, romiplostim. In two, multicentre, randomized, placebo‐controlled, double‐blinded, phase III trials, romiplostim was able to increase and sustain platelet counts in both splenectomized and non‐splenectomized patients. Eighty‐three per cent (69/83) of the romiplostim‐treated patients achieved an overall platelet response compared with 7% (3/42) of patients receiving placebo (P < 0.0001; Cochran–Mantel–Haenszel test controlled for splenectomy and baseline concurrent ITP therapy). Patients from the romiplostim studies, with platelet counts below 50 × 109/L, were able to enter a long‐term, open‐label, extension study. The results of the long‐term study showed that platelet counts above 50 × 109/L were maintained for ≥10, ≥25 and ≥52 consecutive weeks by 78% (102/131), 54% (66/122) and 35% (29/84) of patients, respectively. Romiplostim appears to be generally well tolerated and several patients have now been treated for more than 3 yrs. Most adverse events tend to be mild to moderate in nature. Romiplostim provides a valid treatment option that may bring about a change in the way that patients with ITP are treated in the future. Further studies are now being undertaken in paediatric patients with ITP, patients with myelodysplastic syndrome and patients with chemotherapy‐induced thrombocytopenia.Keywords
This publication has 15 references indexed in Scilit:
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialThe Lancet, 2008
- AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPNew England Journal of Medicine, 2006
- An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpuraBritish Journal of Haematology, 2006
- Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligandClinical Pharmacology & Therapeutics, 2004
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpuraBlood, 2004
- Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitroBlood, 2003
- Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancyBritish Journal of Haematology, 2003
- Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 2002
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994